NEW YORK, Nov. 9, 2011 (GLOBE NEWSWIRE) -- Ventrus BioSciences, Inc. (Nasdaq:VTUS) announced today that it will report on its clinical trial progress, the initial topline results of a market research study commissioned by it and conducted by Princeton Biometrics on the U.S. market for hemorrhoids and iferanserin (VEN-309), and third quarter 2011 financial results.